Effects of platelet-activating factor receptor antagonist (PAFRA) on selected inflammatory and biochemical parameters in lipopolysaccharide-induced rat endotoxemia model;Lipopolisakkarit ile indüklenen rat endotoksemi modelinde bazı yangısel ve biyokimyasal parametreler üzerine platelet aktive edici faktör reseptör antagonisti (PAFRA)'nin etkileri

Kafkas Universitesi Veteriner Fakultesi Dergisi

Volumn 19, Issue 1, 2013, Pages 97-102

  Çöl, Ramazan ^a   Keskin, Ercan ^a  

^a Faculty of Veterinary Medicine   (Turkey)

Author keywords

Biochemical parameters; Cytokines; Endotoxin; Platelet activating factor Receptor antagonist; Rat

Indexed keywords

EID: 84870922129     PISSN: 13006045     EISSN: None     Source Type: Journal    
DOI: 10.9775/kvfd.2012.7255     Document Type: Article

References (53)

1. Møller S, Laigaard F, Olgaard K, Hemmingsen C: Effect of 1,25-dihydroxy-vitamin D3 in experimental sepsis. Int J Med Sci, 4, 190-195, 2007.
2. Çöl R, Durgun Z: Effect of recombinant interleukin-10 on some haematological and biochemical parameters in a rat endotoxaemic model. Acta Vet Hung, 59, 237-245, 2011.
3. Hryszko T, Inaba K, Ihara H, Suzuki Y, Mogami H, Urano T: Nafamostatattenuated the impairment of fibrinolysis in animal sepsis model bysuppressing the increase of plasminogen activator inhibitor type 1. J Trauma, 60, 859-864, 2006.
4. Çöl R, Durgun Z: Effect of vasoactive intestinal peptide (VIP) on cytokinelevels and haemostatic and biochemical parameters in a rat endotoxaemic model. Bull Vet Inst Pulawy, 56, 63-67, 2012.
5. van Westerloo DJ, Giebelen IAJ, Meijers JCM, Daalhuisen J, de Vos AF, Levi M, van der Poll T: Vagus nerve stimulation inhibits activation ofcoagulation and fibrinolysis during endotoxemia in rats. J Thromb Haemost,4, 1997-2002, 2006.
6. Gonzalez-Rey E, Chorny A, Robledo G, Delgado M: Cortistatin, a new antiinflammatory peptide with therapeutic effect on lethal endotoxemia. J Exp Med, 203, 563-571, 2006.
7. Cheng T, Mathews K, Abrams-Ogg A, Wood D: The link between inflammation and coagulation: influence on the interpretation of diagnosticlaboratory tests. Compend Contin Educ Vet, 33, E1-E12, 2011.
8. Jeschke MG, Rensing H, Klein D, Schubert T, Mautes AE, Bolder U, Croner RS: Insulin prevents liver damage and preserves liver function inlipopolysaccharide-induced endotoxemic rats. J Hepatol, 42, 870-879, 2005.
9. Fernández-Martínez E, Morales-Ríos MS, Pérez-Alvarez V, Muriel P: Immunomodulatory effects of thalidomide analogs on LPS-induced plasmaand hepatic cytokines in the rat. Biochem Pharmacol, 68, 1321-1329, 2004.
10. Grypioti AD, Kostopanagiotou G, Demopoulos CA, Roussos A, Mykoniatis M: Platelet activating factor (PAF) antagonism with ginkgolide B protects the liver against acute injury. importance of controlling the receptor of PAF. Dig Dis Sci, 53 (4): 1054-1062, 2008.
11. Koltai M, Hosford D, Gui{dotless}not P, Esanu A, Braquet P: PAF, a review of itseffects, antagonists and possible future implications (Part 1). Drugs, 42, 9-29, 1991.
12. Suputtamongkol Y, Intaranongpai S, Smith MD, Angus B, Chaowagul W, Permpikul C, Simpson JA, Leelarasamee A, Curtis L, White NJ: Adouble-blind placebo-controlled study of an infusion of lexipafant (Platelet-activating factor receptor antagonist) in patients with severe sepsis. Antimicrob Agents Chemother, 44, 693-696, 2000.
13. Horkheimer I, Schuster DP: The role of platelet-activating factor in sepsis: A bench-to-bedside review. Advances In Sepsis, 2 (1): 2-7, 2002.
14. Yost CC, Weyrich AS, Zimmerman GA: The platelet activating factor (PAF) signaling cascade in systemic inflammatory responses. Biochimie, 92(6): 692-697, 2010.
15. Xia SH, Hu CX, Zhao ZL, Xia GD, Di Y: Significance of platelet activatingfactor receptor expression in pancreatic tissues of rats with severe acute pancreatitis and effects of BN52021. World J Gastroenterol, 13 (21): 2992-2998, 2007.
16. Travers J, Pei Y, Morin SM, Hood AF: Antiinflammatory activity of the platelet-activating factor receptor antagonist A-85783. Arch Dermatol Res, 290 (10): 569-573, 1998.
17. SPSS: SPSS Release 15.0 Statistical packet program, SPSS for Windows. SPSS Inc., Chicago, IL. 2006.
18. Hopper, K, Bateman, S: An updated view of hemostasis: mechanisms of hemostatic dysfunction associated with sepsis. J Vet Emerg Crit Care, 15, 83-91, 2005.
19. Han SJ, Ko HM, Choi JH, Seo KH, Lee HS, Choi EK, Choi IW, Lee HK, Im SY: Molecular mechanisms for lipopolysaccharide-induced biphasic activationof nuclear factor-kappa B (NF-kappa B). J Biol Chem, 277 (47): 44715-44721,2002.
20. Moreno SE, Alves-Filho JC, Rios-Santos F, Silva JS, Ferreira SH, Cunha FQ, Teixeira MM: Signaling via platelet-activating factor receptors accounts for the impairment of neutrophil migration in polymicrobial sepsis. J Immunol, 177 (2): 1264-1271, 2006.
21. McManus LM, Pinckard RN: PAF, a putative mediator of oral inflammation. Crit Rev Oral Biol Med, 11, 240-258, 2000.
22. Asakura H, Takahashi Y, Kubo A, Ontachi Y, Hayashi T Omote M, Arahata M, Kadohira Y, Maekawa M, Yamazaki M, Morishita E, Takami A, Yoshida T, Miyamoto K, Nakao S: Immunoglobulin preparations attenuate organ dysfunction and hemostatic abnormality by suppressing the production of cytokines in lipopolysaccharide-induced disseminatedintravascular coagulation in rats. Critical Care Medicine, 34, 2421-2425, 2006.
23. Iba T, Miyasho T: Danaparoid sodium attenuates the increase in inflammatory cytokines and preserves organ function in endotoxemic rats. Critical Care, 12, R86, 2008.
24. Mathiak G, Grass G, Herzmann T, Luebke T, Zetina CC, Boehm SA, Bohlen H, Neville LF and Hoelscher AH: Caspase-1-inhibitor ac-YVAD-cmk reduces LPS lethality in rats without affecting haematology or cytokineresponses. Br J Pharmacol, 131, 383-386, 2000.
25. Ishii S, T Nagase, F Tashiro, K Ikuta, S Sato, I Waga, K Kume, J Miyazaki, T Shimizu: Bronchial hyperreactivity, increased endotoxin lethality andmelanocytic tumorigenesis in transgenic mice overexpressing platelet-activating factor receptor. EMBO J, 16, 133-142, 1997.
26. Tang, HM, Teshima DY, Lum BKB: Effects of the PAF antagonist Befafantand L-659,989 in endotoxic and septic shock. Drug Dev Res, 29, 216-221, 1993.
27. Ogata M, Nandate K, Kawasaki T, Kawasaki C, Ozaki M, ShigematsuA: A platelet activating factor receptor antagonist inhibits cytokine production in human whole blood by bacterial toxins and live bacteria. Anesth Analg, 98 (6): 1767-1772, 2004.
28. Lo CJ, Cryer HG, Fu M, Kim B: Endotoxin-induced macrophage gene expression depends on platelet-activating factor. Arch Surg, 132, 1342-1347, 1997.
29. Ishii S, Nakamura M, Waga I, Kume K, Izumi T, Shimizu T: Cloning andcharacterization of a murine platelet-activating factor receptor gene. Adv Exp Med Biol, 407, 347-355, 1997.
30. Im SY, Han SJ, Ko HM, Choi JH, Chun SB, Lee DG, Ha TY, Lee HK: Involvement of nuclear factor kappa B in platelet-activating factor-mediatedtumor necrosis factor-alpha expression. Eur J Immunol, 27, 2800-2804, 1997.
31. Wang H, Tan X, Chang H, Gonzalez-Crussi F, Remick DG, Hsueh W: Regulation of platelet-activating factor receptor gene expression in vivo by endotoxin, plateletactivating factor and endogenous tumour necrosis factor. Biochem J, 322, 603-608, 1997.
32. Diaz Padilla N, Bleeker WK, Lubbers Y, Rigter GM, Van Mierlo GJ, Daha MR, Hack CE: Rat C-reactive protein activates the autologouscomplement system, Immunology, 109, 564-571, 2003.
33. Çöl R, Keskin E, Atalay B: Effect of pentoxifylline on endotoxin-inducedhaemostatic disturbances in rabbits. Acta Vet Hung, 53, 325-335, 2005.
34. Yang H, Li QW, Han Z S, Hu JH, Li WY, Liu ZB: Recombinant human antithrombin expressed in the milk of non-transgenic goats exhibits high efficiency on rat DIC model. J Thromb Thrombolysis, 28, 449-457, 2009.
35. Zhou W, Chao W, Levine BA, Olson MS: Role of plateletactivating factorin hepatic responses after bile duct ligation in rats. Am J Physiol, 263, G587-G592, 1992.
36. Coker A, Coker I, Huseyinov A, Sokmen S, Karademir S: Is mannitol effective against platelet-activating factor (PAF)-induced liver damage in obstructive jaundice? Hepatogastroenterology, 48, 1134-1137, 2001.
37. Yang Y, Nemoto EM, Harvey SA, Subbotin VM, Gandhi CR: Increasedhepatic platelet activating factor (PAF) and PAF receptors in carbon tetrachloride induced liver cirrhosis. Gut, 53, 877-883, 2004.
38. Grypioti AD, Theocharis SE, Papadimas GJ, Demopoulos CA, Papadopoulou-Daifoti Z, Basayiannis AC, Lykoniatis LG: Platelet-Activating Factor (PAF) involvement in acetaminophen-induced liver toxicity and regeneration. Arc Toxicol, 79, 466-474, 2005.
39. Yazar E, Col R, Uney K, Atalay B, Elmas M, Tras B: Effect of pentoxifyllineon biochemical parameters in endotoxaemic New Zealand White Rabbits. Bull Vet Inst Pulawy, 48, 297-299, 2004.
40. Memon RA, Grunfeld C, Moser AH, Feingold KR: Tumor necrosis factor mediates the effects of endotoxin on cholesterol and triglyceride metabolismin mice. Endocrinology, 132, 2246-2253, 1993.
41. Fraunberg P, Schaefer S, Werdan K, Walli AK, Seidel D: Reduction of circulating cholesterol and apolipoprotein levels during sepsis. Clin Chem Lab Med, 37, 357-362, 1999.
42. Al-Dughaym AM: Some endotoxin-induced clinical and biochemical changes in plasma of camels (Camelus dromedarius). Vet Res Commun, 28, 711-718, 2004.
43. Inarrea P, Gomez-Cambronero J, Nieto M, Sanchez Crespo M: Characteristics of the binding of plateletactivating factor to platelets of different animal species. Eu J Pharmacol, 105, 309-315, 1984.
44. Rabinovici R, Esser KM, Lysko PG, Yue T, Griswold DE, Hillegass LM, Bugelski PJ, Hallenbeck JM, Feuerstein G: Priming by platelet-activatingfactor of endotoxin-induced lung injury and cardiovascular shock. Circ Res,69, 12-25, 1991.
45. van Devender SJH, Buller HR, ten Cate JW, Aareden LA, Hack CE, Sturk A: Experimental endotoxemia in humans: Analysis of cytokine releaseand coagulation, fibrinolytic, and complement pathways. Blood, 76, 2520-2526, 1990.
46. Ding Z, Li S, Wu Z: Mechanisms of endothelial cell-dependent leukocyteadhesion stimulated by platelet-activating factor. Inflammation, 16 (2): 179-186, 1992.
47. Schmidt H, Ebeling D, Bauer H, Bǒhrer H, Gebhard MM, Martin E: Influence of the platelet-activating factor receptor antagonist BN52021 onendotoxin-induced leukocyte adherence in rat mesenteric venules. J Surg Res, 60 (1): 29-35, 1996.
48. Beyer AJ, Smalley DM, Shyr YM, Wood JG, Cheung LY: PAF and CD18mediate neutrophil infiltration in upper gastrointestinal tract during intra-abdominal sepsis. Am J Physiol, 275, G467, 1998.
49. Garland RC, Sun D, Zandi S, Xie F, Faez S, Tayyari F, Frimmel SAF, Schering A, Nakao S, Hafezi-Moghadam A: Noninvasive molecular imaging reveals role of PAF in leukocyte-endothelial interaction in LPS-induced ocular vascular injury. FASEB J, 25, 1284-1294, 2011.
50. Moreno SE, Alves-Filho JC, Rios-Santos F, Silva JS, Ferreira SH, Cunha FQ, Teixeira MM: Signaling via platelet-activating factor receptors accounts for the impairment of neutrophil migration in polymicrobial sepsis. Immunol, 177 (2): 1264-1271, 2006.
51. Schmidt H, Ebeling D, Bauer H, Böhrer H, Gebhard MM, Martin E: Influence of the platelet-activating factor receptor antagonist BN52021 onendotoxin-induced leukocyte adherence in rat mesenteric venules. J Surg Res, 60, 29-35, 1996.
52. Coughlan AF, Hau H, Dunlop LC, Berndt MC, Hancock WW: P-selectinand platelet-activating factor mediate initial endotoxin-induced neutropenia. J Exp Med, 179, 329-334, 1994.
53. Defaux JP, Thonier F, Baroggi N, Etienne A, Braquet P: Involvement ofplatelet-activating factor (PAF) in endotoxin-or ischaemia-induced intestinal hyperpermeability in the rat. J Lipid Mediat: 7, 11-21, 1993.